Squamous Cell Carcinoma Clinical Trial
Official title:
Afatinib and Nivolumab for Treatment of Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN) Not Previously Treated With Immunotherapy.
This phase I/Ib trial will assess the dose, safety and side effects of the combination of the cancer drugs afatinib (GILOTRIF®) and nivolumab (OPDIVO®) and to assess the anti-cancer effects of this combination of drugs when used to treat patients with advanced head and neck cancers that did not respond to previous treatments.
Primary Objectives:
Phase I: To determine dose limiting toxicities (DLTs) and maximum tolerated dose (MTD) of
afatinib when given in combination with nivolumab for subjects with recurrent/metastatic
Squamous Cell Carcinoma of the Head and Neck not previously treated with immunotherapy
Phase IB: To determine long term safety of afatinib in combination with nivolumab when
administered to subjects with recurrent/metastatic Squamous Cell Carcinoma of the Head and
Neck who had experienced disease progression during or after platinum- and cetuximab-based
chemotherapy regimen.
Secondary Objectives:
To assess progression free survival and overall survival of afatinib in combination with
nivolumab when given to subjects with recurrent/metastatic Squamous Cell Carcinoma of the
Head and Neck not previously treated with immunotherapy.
To estimate HPV stratified ORR as assessed by irRECIST in recurrent/metastatic Squamous Cell
Carcinoma of the Head and Neck not previously treated with immunotherapy.
Exploratory Objectives:
- Determination of key molecular alterations that may confer treatment resistance.
Specifically, we will examine key somatic mutations in ERBB1 (exons 18-21), ERBB2 (exon
20), and BRAF (V600) genes. We will further characterize the expression levels of ErbB2
and phosphatase and tensin homolog (PTEN) in tumor samples.
- Characterization of active CD8+ T-cell density and PD-L1 expression levels in the tumor
parenchyma pre- and on-treatment. Immunogenicity will be assessed by expression and
localization of key molecules PD-1, PD-L1, CTLA-4, TIM-3, LAG-3 and OX40 within the
tumor parenchyma.
- Characterization of circulating monocytic myeloid-derived suppressor cells (m-MDSCs)
frequency from pre-treatment peripheral blood samples.
- Characterization of HBD3 expression in the tumor parenchyma from pre-treatment tumor
tissue samples.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Terminated |
NCT02213133 -
Selinexor Treatment of Advanced Relapsed/Refractory Squamous Cell Carcinomas
|
Phase 2 | |
| Not yet recruiting |
NCT04533321 -
A Biomarker-implemented Clinical Study Evaluating Mutations in MET and TP53 in a Population of Treatment-refractory Squamous Cell Carcinoma
|
Phase 2 | |
| Terminated |
NCT02890368 -
Trial of Intratumoral Injections of TTI-621 in Subjects With Relapsed and Refractory Solid Tumors and Mycosis Fungoides
|
Phase 1 | |
| Active, not recruiting |
NCT01232374 -
Nimotuzumab in Combination With Chemoradiation for Local Advanced Esophageal Squamous Cell Carcinoma
|
Phase 2 | |
| Completed |
NCT01208883 -
A Feasibility Study On Continuous Adaptive [18f]Fdg-Pet-Guided Radiotherapy For Head and Neck Cancer
|
Phase 1 | |
| Withdrawn |
NCT01148082 -
School Response to Families Who Have Children With Cancer
|
N/A | |
| Completed |
NCT01089803 -
Observational Study of Swallowing Function After Treatment of Advanced Laryngeal Cancer
|
N/A | |
| Terminated |
NCT00707655 -
Zalutumumab in Combination With Radiotherapy in Head and Neck Cancer Patients Ineligible for Platinum Based Chemotherapy
|
Phase 1/Phase 2 | |
| Completed |
NCT00793169 -
Serum Concentration of Lidocaine After Local Injection During Mohs Micrographic Surgery
|
||
| Completed |
NCT01127737 -
Warning Signs of Squamous Cell Carcinoma and Prevention of SCC by at Risk Organ Transplant Recipients
|
N/A | |
| Completed |
NCT00586040 -
Photochemical Tissue Bonding
|
Phase 2 | |
| Completed |
NCT00409565 -
A Phase II Trial of Cetuximab and Bevacizumab in Patients With Recurrent or Metastatic Head and Neck Cancer
|
Phase 2 | |
| Completed |
NCT00176267 -
Paclitaxel, Carboplatin And Low Dose Radiation As Induction Therapy In Locally Advanced Head And Neck Cancer
|
Phase 2 | |
| Terminated |
NCT04685798 -
Optimized Diffusion-Weighted Imaging for the Evaluation of Post-Treatment Squamous Cell Carcinoma in the Neck: Comparative Study With FDG PET/CT
|
N/A | |
| Recruiting |
NCT04370587 -
A Clinical Study of Intratumoral MVR-T3011 (T3011) Given as a Single Agent and in Combination With Intravenous Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors
|
Phase 1/Phase 2 | |
| Recruiting |
NCT04475952 -
Early Diagnosis of Upper Digestive Tract Disease
|
||
| Recruiting |
NCT04435938 -
A Study of SBRT for Squamous Cell Carcinoma of the Head and Neck
|
Phase 2 | |
| Not yet recruiting |
NCT05852665 -
Buccal Cancer Resection Ultrasound Guided
|
N/A | |
| Recruiting |
NCT05048459 -
Comparing Two Surveillance Approaches for People Who Have Received Treatment for HPV-associated Head and Neck Cancer and Show No Signs of Disease
|
N/A | |
| Suspended |
NCT03952585 -
De-intensified Radiation Therapy With Chemotherapy (Cisplatin) or Immunotherapy (Nivolumab) in Treating Patients With Early-Stage, HPV-Positive, Non-Smoking Associated Oropharyngeal Cancer
|
Phase 2/Phase 3 |